Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes

2016 ◽  
Vol 33 (11) ◽  
pp. 1055-1057 ◽  
Author(s):  
Eduardo Bancalari
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Pulmonary Blood Flow ◽  
Ductus Arteriosus ◽  
Lung Damage ◽  
Early Closure ◽  
Short And Long Term ◽  
Respiratory Outcomes ◽  
Patent Ductus

The patency of the ductus arteriosus is very common in extremely premature infants. The increased pulmonary blood flow that results from left-to-right ductal shunting can produce an acute deterioration in lung function and some data suggest that it may increase the risk of chronic lung damage. However, there is no clear evidence that prophylactic or early closure of the patent ductus arteriosus (PDA) results in a clear reduction in bronchopulmonary dysplasia. For this reason, and because of the side effects of the available therapies to close the ductus, there is a wide variation in the approach to the PDA in this population and most clinicians will intervene to close the ductus only in cases of significant shunt with hemodynamic decompensation.

Renal Calcifications: A Complication of Long-Term Furosemide Therapy in Preterm Infants

PEDIATRICS ◽  
1982 ◽  
Vol 70 (3) ◽  
pp. 360-363 ◽  
Author(s):  
Karen G. Hufnagle ◽  
Shadid N. Khan ◽  
Duna Penn ◽  
Alexander Cacciarelli ◽  
Paul Williams
Keyword(s):  
Calcium Phosphate ◽  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Chronic Lung Disease ◽  
Stone Formation ◽  
Ductus Arteriosus ◽  
Probable Mechanism ◽  
Calcium Excretion ◽  
Patent Ductus

During the last four years ten premature infants developed renal calcifications while receiving long-term furosemide therapy. The drug was used in infants with patent ductus arteriosus and later in the same infants with chronic lung disease. They had received furosemide in a dose of at least 2 mg/kg/day for at least 12 days before calcifications were noted on abdominal roentgenograms. Calcifications included small flecks, isolated stones, staghorn calculi, and nephrocalcinosis. Analysis of stones received from four infants showed calcium oxalate and calcium phosphate. Infants who were not receiving furosemide had no calcifications. The infants with renal calcifications had rates of calcium excretion ten to 20 times that of normal, age-matched premature infants in our nursery. When chlorothiazide was given to the infants, in addition to furosemide, a four- to 15-fold decrease in calcium excretion and a radiologic dissolution of the renal calcifications were documented. It is concluded that furosemide, in doses of at least 2 mg/kg/day for at least 12 days can be associated with renal calcifications. The probable mechanism of the stone formation is hypercalciuria, primarily caused by furosemide.

scholarly journals Long-term Results of Ligation of Patent Ductus Arteriosus in Premature Infants.

1992 ◽  
Vol 21 (1) ◽  
pp. 35-40
Author(s):  
Tohru SAKURADA ◽  
Ryosei KURIBAYASHI ◽  
Satoshi SEKINE ◽  
Hiroaki AIDA ◽  
Keiji SEKI ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Ductus Arteriosus ◽  
Long Term Results ◽  
Patent Ductus

scholarly journals Management of Patent Ductus Arteriosus in Premature Infants in 2020

2021 ◽  
Vol 8 ◽  
Author(s):  
Sarah Parkerson ◽  
Ranjit Philip ◽  
Ajay Talati ◽  
Shyam Sathanandam
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Paradigm Shift ◽  
Ductus Arteriosus ◽  
Cardiac Condition ◽  
Practice Variations ◽  
Patent Ductus

The patent ductus arteriosus (PDA) is the most commonly found cardiac condition in neonates. While there have been several studies and thousands of publications on the topic, the decision to treat the PDA is still strongly debated among cardiologists, surgeons, and neonatologists. This is in part due to the shortage of long-term benefits with the interventions studied. Practice variations still exist within sub-specialties and centers. This article briefly summarizes the history, embryology and histology of the PDA. It also succinctly discusses the hemodynamic significance of a PDA which builds the framework to review all the available literature on PDA closure in premature infants, though not a paradigm shift just yet; it introduces transcatheter PDA closure (TCPC) as a possible armament to the clinician for this age-old problem.

Late manifestation coarctation of the aorta in a premature infant 4-month post-percutaneous device closure of a patent ductus arteriosus

2019 ◽  
Vol 29 (12) ◽  
pp. 1556-1558
Author(s):  
Ryan M. Serrano ◽  
Mark D. Rodefeld ◽  
Ryan Alexy
Keyword(s):  
Patent Ductus Arteriosus ◽  
Premature Infants ◽  
Ductus Arteriosus ◽  
Coarctation Of The Aorta ◽  
Percutaneous Closure ◽  
Device Closure ◽  
Percutaneous Device ◽  
Favourable Safety ◽  
Patent Ductus

AbstractPatent ductus arteriosus is the most common cardiovascular abnormality in premature infants. With newly available percutaneous devices, centres are reporting high rates of success and favourable safety profiles with percutaneous closure of haemodynamically significant ductus arteriosi in infants under 1000 g. We report the case of a 5-week-old, previous 25-week gestation, 1200-g infant who underwent successful percutaneous closure of a ductus arteriosus with a Medtronic Microvascular Plug but who developed late-term coarctation from the device. This case should prompt practitioners to consider the need and timing of follow-up echocardiograms in this population and sheds light on a newly reported long-term complication of device closure in premature infants.

Sign in / Sign up

Export Citation Format

Share Document